From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

This Giant Pharma is Working on Three Promising Fronts to Beat the Virus. Surely Its Shares Should Rise Before Long

By Malcolm Stacey | Thursday 9 April 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Hello, Share Collectors. Today’s choice is probably the last in my humble series of medical companies possibly to see fast-escalating share prices once the crisis is over. This is one of the biggest pharmas directly involved in the fight against the outbreak. I don’t hold shares in AstraZeneca (AZN), having chosen instead its big rival GlaxoSmithKline (GSK), but my finger will hover on the buy button once the outbreak peak is over...

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 14:46:26